TG Therapeutics, Inc. (TGTX)
$25.49
Rating:
Recommendation:
Neutral
| Symbol | TGTX |
|---|---|
| Price | $25.49 |
| Beta | 2.081 |
| Volume Avg. | 4.26M |
| Market Cap | 3.808B |
| Shares () | - |
| 52 Week Range | 3.48-35.67 |
| 1y Target Est | - |
| DCF Unlevered | TGTX DCF -> | |
|---|---|---|
| DCF Levered | TGTX LDCF -> | |
| ROE | -173.03% | Strong Sell |
| ROA | -102.46% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 230.40% | Strong Buy |
| P/E | -20.56 | Strong Sell |
| P/B | 58.91 | Strong Buy |
Latest TGTX news
About
Download (Excel)TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.